• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    6/15/23 1:31:31 PM ET
    $BBLG
    $CALC
    $CELZ
    $CRVS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBLG alert in real time by email

    Gainers

    • SCWorx (NASDAQ:WORX) stock moved upwards by 128.8% to $0.5 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 84.7 million shares, making up 189144.6% of its average full-day volume over the last 100 days. The company's market cap stands at $6.5 million.
    • Creative Medical Tech (NASDAQ:CELZ) shares moved upwards by 26.82% to $5.73. As of 13:30 EST, Creative Medical Tech's stock is trading at a volume of 542.2K, which is 292.2% of its average full-day volume over the last 100 days. The company's market cap stands at $8.0 million.
    • IO Biotech (NASDAQ:IOBT) shares rose 21.73% to $1.96. Trading volume for this security as of 13:30 EST is 2.1 million, which is 2253.1% of its average full-day volume over the last 100 days. The company's market cap stands at $56.4 million.
    • Verastem (NASDAQ:VSTM) shares rose 21.35% to $11.31. As of 13:30 EST, Verastem's stock is trading at a volume of 463.8K, which is 203.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $189.3 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 20.75% to $0.88. As of 13:30 EST, this security is trading at a volume of 6.4 million shares, making up 195.1% of its average full-day volume over the last 100 days. The company's market cap stands at $24.2 million.
    • Oncology Institute (NASDAQ:TOI) shares moved upwards by 19.77% to $0.59. The current volume of 2.2 million shares is 306.4% of Oncology Institute's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $44.2 million.

    Losers

    • Mersana Therapeutics (NASDAQ:MRSN) stock declined by 58.2% to $4.0 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 24.4 million shares, making up 1242.3% of its average full-day volume over the last 100 days. The company's market cap stands at $456.9 million.
    • Bone Biologics (NASDAQ:BBLG) shares decreased by 55.59% to $1.75. Trading volume for this security as of 13:30 EST is 1.1 million, which is 2293.5% of its average full-day volume over the last 100 days.
    • OncoSec Medical (NASDAQ:ONCS) stock declined by 47.57% to $0.22. As of 13:30 EST, this security is trading at a volume of 3.5 million shares, making up 396.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 million.
    • Corvus Pharma (NASDAQ:CRVS) stock declined by 28.96% to $2.38. Trading volume for this security as of 13:30 EST is 4.4 million, which is 491.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $110.8 million.
    • Mallinckrodt (AMEX:MNK) stock fell 20.64% to $1.0. As of 13:30 EST, this security is trading at a volume of 470.2K shares, making up 32.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.1 million.
    • CalciMedica (NASDAQ:CALC) shares decreased by 16.1% to $4.9. The market value of their outstanding shares is at $27.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BBLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBLG
    $CALC
    $CELZ
    $CRVS

    CompanyDatePrice TargetRatingAnalyst
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    CalciMedica Inc.
    $CALC
    1/29/2026Buy → Neutral
    H.C. Wainwright
    IO Biotech Inc.
    $IOBT
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    IO Biotech Inc.
    $IOBT
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    Verastem Inc.
    $VSTM
    10/16/2025Overweight
    Cantor Fitzgerald
    Corvus Pharmaceuticals Inc.
    $CRVS
    10/13/2025$16.00Overweight
    Barclays
    IO Biotech Inc.
    $IOBT
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

    AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations Company cash, cash equivalents, and

    3/4/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCWorx Announces New SaaS and Data Management Customer Supporting a Prominent Southeastern Healthcare Provider's Workday Platform

    New York, NY, March 04, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:SCWX), a leading provider of data management, analytics, and interoperability solutions for healthcare organizations, today announced that it has signed a new SaaS and data management customer agreement with a prominent Southeastern healthcare provider in support of its implementation and ongoing optimization of its Workday platform. The health system's integrated delivery network (IDN) comprises over 700 beds across multiple acute care hospitals and outpatient facilities, serving communities throughout the region. Under the agreement, SCWorx will provide its cloud-based data management and governance solutions to suppo

    3/4/26 10:11:22 AM ET
    $SCWX
    $WORX
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $BBLG
    $CALC
    $CELZ
    $CRVS
    SEC Filings

    View All

    Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    3/4/26 4:15:33 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Verastem Inc.

    10-K - Verastem, Inc. (0001526119) (Filer)

    3/4/26 4:06:05 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by CalciMedica Inc.

    S-3 - CalciMedica, Inc. (0001534133) (Filer)

    3/3/26 4:54:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paterson Dan sold $6,489 worth of shares (970 units at $6.69), decreasing direct ownership by 0.16% to 612,919 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    2/5/26 4:10:10 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Peter A. exercised 210,000 shares at a strike of $5.33 (SEC Form 4)

    4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

    1/30/26 6:39:04 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Calkins Daniel was granted 16,665 shares, increasing direct ownership by 16% to 121,384 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/23/26 4:58:52 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,675 worth of shares (2,500 units at $3.07) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/22/25 9:35:04 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $9,105 worth of shares (3,400 units at $2.68) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/17/25 9:45:05 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13758646. The

    2/26/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's websit

    2/18/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLG
    $CALC
    $CELZ
    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care